Investors Face August Deadline in ADMA Biologics Securities Lawsuit

The lawsuit, filed by The Rosen Law Firm, alleges that ADMA Biologics misled the market during the specified period. According to the complaint, the company allegedly failed to disclose a related party transaction and employed channel stuffing—a practice used to artificially inflate revenue figures. The suit contends that these actions left the company without adequate internal controls, rendering public statements about its business operations materially false.

Those who held securities during the Class Period are not currently represented by counsel unless they choose to retain an attorney. While investors have the option to remain absent class members, those interested in serving as lead plaintiff must file a motion with the court by the August 10 deadline. The Rosen Law Firm, which is handling the case on a contingency fee basis, notes that prospective plaintiffs may contact Phillip Kim at 866-767-3653 to discuss the litigation process. No class has been certified to date, and the firm emphasizes that prior legal results do not guarantee future outcomes.